药物涂层球囊与普通球囊治疗透析通路失效的系统评价与荟萃分析
该系统评价与荟萃分析比较了药物涂层球囊(DEB)与普通球囊(PBA)治疗动静脉内瘘或人工血管移植物狭窄的疗效。共纳入10项研究,DEB组6个月和1年靶病变一期通畅率均显著高于PBA组,且两组均未观察到主要操作相关并发症。
要点
- DEB治疗透析通路失效的6个月靶病变一期通畅率显著优于PBA。
- DEB的1年靶病变一期通畅率同样显著高于PBA。
- 两组均未发生主要操作相关并发症。
核心结论
- 与普通球囊相比,药物涂层球囊可显著延长透析通路失效患者6个月和1年的靶病变一期通畅率,且安全有效。
研究设计与样本
- 系统评价与荟萃分析,检索PubMed、Embase和MEDLINE数据库至2018年12月,纳入10篇符合标准的研究。
主要发现
- DEB组6个月靶病变一期通畅率为70%,PBA组为54%(OR 2.71,95%CI 1.51-4.85,P<0.01)。
- DEB组1年靶病变一期通畅率为59%,PBA组为37%(OR 3.12,95%CI 2.14-4.55,P<0.01)。
- 两组均未观察到主要操作相关并发症。
关键数值与推荐
- 6个月靶病变一期通畅率:DEB 70% vs. PBA 54%,OR 2.71(95%CI 1.51-4.85),P<0.01。
- 1年靶病变一期通畅率:DEB 59% vs. PBA 37%,OR 3.12(95%CI 2.14-4.55),P<0.01。
临床怎么用
- 对于动静脉内瘘或人工血管移植物狭窄导致的透析通路失效,可考虑使用药物涂层球囊以提高6个月和1年的一期通畅率。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Hemodialysis access dysfunction is the major cause of hospitalization for patients undergoing hemodialysis due to stenosis at the anastomotic site. Our purpose is to perform a meta-analysis comparing target lesion primary patency rates at 6 months and one year, and major procedure-associated complications between drug-eluting balloon (DEB) and plain balloon angioplasty (PBA) for the treatment of arteriovenous fistula (AVF) or synthetic arteriovenous graft (AVG) stenosis. METHODS: PubMed, Embase, and MEDLINE databases were screened up to December 2018 to compare target lesion primary patency and complications between DEB and PBA. Two independent reviewers identified studies fulfilling our inclusion/exclusion criteria, extracted relevant data, and assessed quality. Fixed- or random-effects models were used to calculate overall effect estimates. RESULTS: Our literature search identified 10 articles eligible for inclusion in the review and analysis. DEB provided significantly higher target lesion primary patency rates for failing hemodialysis access than did PBA at 6 months [70% vs. 54%; odds ratio (OR), 2.71, 95% confidence interval (CI), 1.51 to 4.85; P < 0.01] and one year (59% vs. 37%; OR, 3.12, 95% CI, 2.14 to 4.55; P < 0.01). No major procedure-associated complications were observed in the 2 groups. CONCLUSIONS: DEB is an effective and safe technology that can significantly prolong 6-month and one-year target lesion primary patency for failing hemodialysis access when compared to PBA.
引用
- Yuan Y, Cheng W, Lu H, et al. Drug-Eluting Balloon Versus Plain Balloon Angioplasty For The Treatment of Failing Hemodialysis Access: A Systematic Review and Meta-analysis. Ann Vasc Surg. 2019. PMID: 31669341. doi:10.1016/j.avsg.2019.10.062
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。